What is the therapeutic effect of Ripotinib as a lung cancer drug?

Repotrectinib (Repotrectinib) is a targeted therapy for lung cancer. It is mainly used to treat tumors related to NTRK and ROS1 gene fusion. NTRK gene fusion produces abnormal TRK proteins, while ROS1 gene fusion produces abnormal ROS1 fusion proteins. These abnormal proteins cause cancer cells to lose control and cause tumors to grow rapidly.

In clinical studies, Ripotinib has demonstrated significant efficacy in patients with ROS1 gene fusion non-small cell lung cancer. About 77% (93 out of 121) of patients who had not received any treatment with drugs that block the ROS1 protein experienced a shrinkage of their cancers after taking repotinib. The average duration of this response was 34 months, indicating that repotinib can effectively inhibit tumor development when it is first administered.

For patients who have received otherROS1 protein-blocking drugs, Ripotinib also shows good efficacy. About 49% (52 of 107) of these patients also saw their cancer shrink, and the average duration of response was 15 months. This result shows that even in previously treated patients, repotinib can still provide a certain degree of therapeutic effect, showing its potential as a later-line treatment drug.

The mechanism of Ripotinib is mainly to prevent the proliferation of cancer cells by blocking the activity ofTRK and ROS1 fusion proteins. This mechanism is not only applicable to patients receiving initial treatment, but also provides new options for subsequent treatment, especially when facing the problem of drug resistance.

In general, repotinib has shown good clinical effects in the treatment of non-small cell lung cancer with ROS1 gene fusion It can effectively delay the progression of cancer and improve the quality of life of patients. This makes repotinib an important innovation in the field of targeted treatment of lung cancer, bringing new hope to patients.

Reference materials:https://www.drugs.com/mtm/repotrectinib.html